Search Site


Answer Centre - Telephone Answering in your Company Name by an Answer Centre PA


Epistem upbeat as value opportunities begin to emerge

28 February 2008

UK biotechnology company Epistem, reported today that it had made good progress in the first six months of the year to 31 December 2007, with sales up to £1.1 million from £0.7 million last time.

The company, which is commercialising its expertise in tissue renewal in the areas of oncology, gastrointestinal diseases and dermatology, saw year-on-year pre-tax losses remain broadly unchanged at £0.5 million.

Epistem cited significant progress on a number of key fronts, including accelerating development of selected therapeutic lead candidates and the completion of a £1.1 million fundraising in November 2007 for its newly emerging biomarker business

Matthew Walls, chief executive of Epistem said: “Following a very successful first half of this financial year, the board of Epistem remain convinced that in the medium term there will be substantial uplift in the value of the company based on its current performance and the value opportunities now beginning to emerge.”






Headlines

31 August 2010

30 August 2010

27 August 2010

20 August 2010

18 August 2010

13 August 2010

09 August 2010

06 August 2010

30 July 2010

29 July 2010

28 July 2010

27 July 2010

26 July 2010

23 July 2010

23 July 2010

22 July 2010

21 July 2010

19 July 2010

16 July 2010

12 July 2010

09 July 2010

08 July 2010

07 July 2010

06 July 2010

05 July 2010

02 July 2010

06 May 2010

13 April 2010

24 March 2010

23 March 2010

23 March 2010

23 March 2010

23 March 2010

23 March 2010

23 March 2010

23 March 2010

23 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

22 March 2010

19 March 2010

19 March 2010

» See all News




© SmallCapNews   |   Contact Us   |   Terms of Use   |   RSS Feeds Site by LunarSafari